Regeneron Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSu...
Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
- First Posted Date
- 2013-05-22
- Last Posted Date
- 2017-08-28
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 380
- Registration Number
- NCT01859988
Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-03-04
- Last Posted Date
- 2013-03-04
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT01803321
Study to Assess the Safety and Tolerability of Single Doses of REGN1500
- First Posted Date
- 2012-12-17
- Last Posted Date
- 2016-05-12
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 99
- Registration Number
- NCT01749878
Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-11-21
- Last Posted Date
- 2020-04-07
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 305
- Registration Number
- NCT01730053
- Locations
- 🇪🇸
(2 Locations), Barcelona, Spain
🇲🇽(3 Locations), Guadalajara, Mexico
Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-11-21
- Last Posted Date
- 2015-08-31
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 355
- Registration Number
- NCT01730040
Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer
- First Posted Date
- 2012-11-16
- Last Posted Date
- 2015-04-06
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 56
- Registration Number
- NCT01727869
Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-11-06
- Last Posted Date
- 2017-12-22
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 154
- Registration Number
- NCT01722045
Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1033 (SAR391786)
- First Posted Date
- 2012-11-02
- Last Posted Date
- 2013-09-12
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT01720576
Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-10-18
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 249
- Registration Number
- NCT01709500
Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-10-18
- Last Posted Date
- 2020-06-23
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 314
- Registration Number
- NCT01709513
© Copyright 2024. All Rights Reserved by MedPath